MIRM News and Press, Mirum Pharmaceuticals Inc. From 05/04/23

- $31.6 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) toda...

2023-04-30 07:34:21 ET Summary Today, we circle back on Mirum Pharmaceuticals for the first time since late 2021. The stock has risen some 70% over that time thanks to the successful launch of Livmarli. The company also has numerous potential catalysts/milestones on the horizo...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first quarter 2023 financial results and recent corporate progress. Conference call details: Th...

2023-04-13 03:47:03 ET Mirum Pharmaceuticals ( NASDAQ: MIRM ) prices its offering of $275M aggregate principal amount of 4.00% convertible senior notes due 2029 in a private offering. The offering size was increased from the previously announced offering size of $200M agg...

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Ru...

2023-04-12 09:20:49 ET Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q1 Revenue of $31.5M. Approximately $232.1 million of cash, cash equivalents, restricted cash equivalents and short‐term investments as of March 31, 2023; These are all  company&#x...

2023-04-12 07:05:50 ET Mirum Pharmaceuticals ( NASDAQ: MIRM ) intends to offer $200M aggregate principal amount of convertible senior notes due 2029 in a private offering to qualified institutional buyers. The initial purchasers of the notes will have an option to purchase, fo...

Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institut...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023. The company’s preliminary unaudited financial results for the first quarter of 2023 include: Approximately $31.5 million of tota...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that Tim Walbert has been appointed to the company’s Board of Directors. In addition to Mr. Walbert’s appointment, the company shared that Niall O’Donnell, Ph.D., a Mirum director since November 2018, has announced hi...